Are Anti-Receptor-Binding Domain Antibodies Still a Relevant Proxy for Monitoring SARS-CoV-2 Neutralizing Activity in the Omicron Era?
Kahina SakerBruno PozzettoAntonin BalMartine ValetteJean Baptiste FassierCarla SaadeMary Anne TrabaudSophie Trouillet-Assantnull nullPublished in: Clinical chemistry (2022)